DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01687582

CompletedPhase NA

Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Assets

Exenatide / Liraglutide

Listed sites

1

Recruiting sites

—

Enrollment

10

actual

Study population

Psoriasis / psoriatic arthritis, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Improvement of PASI score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01687582
Org study IDUCL-DIAB-02

Timeline

Milestones

Study first posted2012-09-19estimated
Last update posted2019-03-12actual
Study start2012-01 (month precision)
Primary completion2012-12actual (month precision)
Study completion2013-03actual (month precision)

Assets

Investigational agents

ExenatideLiraglutide

Study populations

Who this study enrolls

Psoriasis / psoriatic arthritisType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetic patients treated with oral anti-hyperglycaemic agents and/or insulin and presenting stable psoriasis plaques for at least one year, which failed to respond to previous systemic and/or topical treatments.

Exclusion criteria

•Type 1 diabetes
•Secondary diabetes
•Liver, renal or pancreatic disease
•Previous treatment with GLP-1 agonist or DPP-4 inhibitors agents

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Other clinical outcomes
2
Glycemic / diabetes
1
Safety / tolerability / PK
1
Other (unclassified)
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

Evolution of BMI (body mass index)

Time frame:4 to 6 months

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Evolution of BMI

Time frame:4 to 6 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Evolution of glycaemic control

Time frame:4 to 6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Evolution of routine laboratory measures

Time frame:4 to 6 months

descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Improvement of PASI score

Time frame:4 to 6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Evolution of histopathological data

Time frame:4 to 6 months

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Evolution of immunological data

Time frame:4 to 6 months

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.